Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention

Petrykiv, S.; Laverman, Gozewijn D.; Persson, Frederik; Vogt, Liffert; Rossing, Peter; Borst, Martin H. de; Gansevoort, Ronald; Zeeuw, Dick de; Heerspink, Hiddo J.L.

doi:10.2215/cjn.00390117

Cited by 6 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Aldosterone blockade reduces cardiovascular mortality in patients with heart failure and also reduces albuminuria. [40][41][42] However, the absolute risk-benefit ratio for aldosterone blockade in GN remains unclear.…”

Section: Genetic Testing In Kidney Diseasementioning

confidence: 99%

Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference

Floege

Barbour

Cattran

et al. 2020

Nefrologiâ (St.-Peterbg.)

130

View full text Add to dashboard Cite

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline’s publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.

show abstract

Section: Genetic Testing In Kidney Diseasementioning

confidence: 99%

Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference

Floege

Barbour

Cattran

et al. 2020

Nefrologiâ (St.-Peterbg.)

130

View full text Add to dashboard Cite

show abstract

“…In some albuminuria end point studies, patients who respond in the first months, in comparison with those who do not respond at all or who respond later, show the greatest risk reduction of developing hard end points in the long term [85, 86]. Moreover, the variability in albuminuria response is reproducible upon re-exposure to a drug, when an anti-albuminuric drug is up-titrated or when another drug of the same class is administered [87, 88].…”

Section: Precision Nephrology In Intervention Studies: Reducing Variamentioning

confidence: 99%

Precision Nephrology Is a Non-Negligible State of Mind in Clinical Research: Remember the Past to Face the Future

Provenzano

Nicola

Pena

et al. 2020

Nephron

View full text Add to dashboard Cite

CKD is a major public health problem. It is characterized by a multitude of risk factors that, when aggregated, can strongly modify outcome. While major risk factors, namely, albuminuria and low estimated glomerular filtration rate (eGFR) have been well analyzed, a large variability in disease progression still remains. This happens because (1) the weight of each risk factor varies between populations (general population or CKD cohort), countries, and single individuals and (2) response to nephroprotective drugs is so heterogeneous that a non-negligible part of patients maintains a high cardiorenal risk despite optimal treatment. Precision nephrology aims at individualizing cardiorenal prognosis and therapy. The purpose of this review is to focus on the risk stratification in different areas, such as clinical practice, population research, and interventional trials, and to describe the strategies used in observational or experimental studies to afford individual-level evidence. The future of precision nephrology is also addressed. Observational studies can in fact provide more adequate findings by collecting more information on risk factors and building risk prediction models that can be applied to each individual in a reliable fashion. Similarly, new clinical trial designs can reduce the individual variability in response to treatment and improve individual outcomes.

show abstract

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Floege

Barbour²,

Cattran

et al. 2019

Kidney International

206

111

View full text Add to dashboard Cite

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline's publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.

show abstract

Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention

Cited by 6 publications

References 33 publications

Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference

Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference

Precision Nephrology Is a Non-Negligible State of Mind in Clinical Research: Remember the Past to Face the Future

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference

Contact Info

Product

Resources

About